AbCellera Biologics(ABCL.US)獲Truist Securities首次覆蓋，給予買入評級, 目標價29.00美元。 AbCellera Biologics（ABCL.US）公司簡介：AbCellera Biologics, Inc. engages in the development of therapeutic antibo...
AbCellera Biologics(ABCL.US)獲Truist Securities首次覆蓋，給予買入評級, 目標價29.00美元。
AbCellera Biologics（ABCL.US）公司簡介：AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, V閞onique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.
以上內容由證券之星根據公開信息整理，與本站立場無關。證券之星力求但不保證該信息（包括但不限于文字、視頻、音頻、數據及圖表）全部或者部分內容的的準確性、完整性、有效性、及時性等，如存在問題請聯系我們。本文為數據整理，不對您構成任何投資建議，投資有風險，請謹慎決策。
jay
